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Abstract 
Previous studies have demonstrated that repeated administration of 17β-
estradiol (E-2) at a dose of 1mg/kg to both (SWR x NZB)F1 (SNF1) mice and 
(DBA x BALB/c)F1(DBF1) mice resulted in significantly decreased survival and 
increased appearance of lupus nephritis pathology. However, the ways in which 
estrogen modulates immune responses has yet to be fully understood, specifically 
in regard to modulations in TH1 and TH2 cytokine profile. Various studies have 
reported the presence of two estrogen receptors (ER), α and β, which have been 
found to be constitutively expressed in many immune cells. In the present project, 
ER chimeric alpha knockout (αERKO), beta knockout (βERKO) and double 
knockout (αβERKO) as well as wild type(WT) mice were injected monthly with 
β-estradiol 17-valerate (E-2) at 1mg/kg. Control mice of each type received oil 
vehicle only. Results showed that TH1 cytokine production by cells from WT 
mice was suppressed by E-2 administration, although IFN-γ production was 
increased in cells from βERKO mice treated with estrogen compared to those 
treated with oil vehicle. TH2 cytokine production was increased in cells from WT 
mice treated with estrogen compared to controls. Increases in the production of 
anti-double stranded DNA antibodies were also observed in cells from αERKO 
mice. These observations suggest a role for differences in ER-α and ER-β 
expression in E-2 induced modulation of immune responses, including 
autoimmune diseases like Systemic Lupus Erythematosus (SLE). 
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INTRODUCTION 
According to one study, it is estimated that approximately 5 percent of 
populations in Western countries is affected by various autoimmune diseases (1). 
The immune system is essential in the recognition of and distinction between self 
and non-self entities.  A typical immune system only generates a humoral and/or 
cellular response to non-self such as pathogens, bacteria, antigens etc. However, 
in some cases the immune system may recognize an individual’s own cells and 
proteins as foreign, causing an autoimmune response. Contrary to what might 
have been thought initially, autoimmunity is a normal process that is important in 
clearing the body of certain pathological self cells (such as the prevention of 
tumor metastasis) and cellular debris.  
According to Davidson and Diamond (2001), autoimmune disease is 
defined as a clinical syndrome caused by the activation of T or B cells, or both, in 
the absence of an ongoing infection or other discernible cause. In other words, 
autoimmune disease is caused by the failure of the proper functioning of the 
body’s defense mechanisms, or a lack of tolerance of one’s own cells. There exist 
two categories of autoimmune diseases. Organ-specific autoimmune diseases, 
such as type 1 diabetes mellitus, are localized in specific tissues in the body. 
Systemic diseases, such as systemic lupus erythematosus (SLE), have a 
widespread effect on several tissue systems in the organism. In general, these 
diseases are caused by, either changes in selection and regulation of T cells or B 
cells, or aberrant reactions to particular self or foreign antibodies (1). 
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While there are many factors that can cause autoimmune disease, genetic 
susceptibility is suggested to play an important role in disease manifestation. This 
has been supported by evidence of familial clustering and higher rates of 
concordance for the diseases in monozygotic twins than in dizygotic twins. 
Certain autoimmune diseases are thought to be caused, in major part, by mutation 
in a single gene. Such is the case of autoimmune lymphoproliferative syndrome, a 
disease with an autosomal dominant heredity pattern resulting from defects in the 
Fas protein (1). Fas protein is essential in mediating apoptotic pathways in the 
body and serves to down-regulate immune responses (1). The defect in the gene 
for the Fas protein results in the organism’s inability to successfully perform 
apoptosis, and therefore delete, activated immune cells that are reactive with self 
antigens.  
It is important to note, however, that not all individuals who possess this 
single gene mutation will develop the disorder. There are many other factors that 
interact to enhance one’s susceptibility to autoimmunity. In fact it has been 
revealed that susceptibility to most autoimmune diseases results from the 
stochastic or simultaneous affects of mutations in many genes. Thus there are 
many susceptibility genes that contribute to the onset of disease in patients. For 
example, there is evidence that the genes for the class I and class II HLA major 
histocompatibility complex molecules, which are responsible for antigen 
presentation by antigen presenting cells (APCs), in association with the tumor 
necrosis factor α gene (TNF-α), are involved in most autoimmune diseases. 
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Furthermore, many autoimmune diseases share common susceptibility genes, 
predisposing individuals to a combination of diseases. 
Although certain individuals possess genes that confer susceptibility to 
disease, in many the onset of autoimmunity may be triggered by environmental 
factors. Two categories of such factors can be distinguished: infectious and non-
infectious agents. In the case of multiple sclerosis for instance, the manifestation 
of the disease is primarily due to both T cell auto-reactivity to a peptide from the 
auto-antigen myelin basic protein, and T cells with reactivity to peptides from the 
Epstein-Barr virus, influenza virus type A, and human papillomavirus. A potential 
explanation is that the onset of disease is initiated by a normal immune response 
to a viral or bacterial infection, which is then sustained, even after elimination of 
the threat, by T cell reactivity to autoantigens that are homologous or “mimic” the 
foreign antigen. 
Various studies have noted a significant sex difference in immune 
responses to antigens. It appears that females in many species are seen to have 
heightened immune responses and are more susceptible to autoimmunity (2, 3). 
Particularly, in Systemic Lupus Erythematosus (SLE), we see a 9:1 ratio in 
predominance of the disease in women as compared to men (6-7). There is also 
evidence of the correlation between steroid hormone levels and the changes in 
clinical manifestation of SLE, which is additionally enhanced during pregnancy 
and the postpartum period (8-10).  Male and female patients with SLE often have 
abnormally high levels of estrogen (hyperestrogenic) and/or abnormally low 
levels of androgen (testosterone) hypoandrogenic (11-13). This correlation is also 
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reinforced by the higher incidence of the disease in patients with Klinefelter’s 
syndrome (14, 15), which is a genetic disease of males that is characterized by a 
variety of sex hormone abnormalities, including increased production of estrogen.  
These data, therefore, point to a potential significant role of estrogen in the 
gender-specific modulation of immune responses involved in autoimmunity. 
Research done in the Gavalchin Lab using the (SWR x NZB) F1
 
(SNF1) 
mouse model for the human autoimmune disease Systemic Lupus Erythematosus 
(SLE) has provided a more direct evidence of the correlation between estrogen 
levels and SLE. Specifically, repeated administration of 17β-estradiol (E-2) at a 
dose of 1mg/kg to male (SWR x NZB)F1 ( SNF1) mice, which do not develop 
lupus unlike SNF1 female mice, beginning at 7 weeks and then monthly thereafter 
for another 4 months, resulted in significantly decreased survival, similar to that 
of female SNF1 mice, compared to vehicle-treated male mice. By the 3rd dose 
(about 20 weeks of age), there was a significant development of excess serum 
protein in the urine (proteinuria), with an additional increase in autoantibodies 
expressing a pathogenic biomarker for lupus,  IdLNF1+, in the serum of E-2 treated 
male SNF1 mice. IdLNF1-reactive T cells with a memory phenotype  
(CD44+CD45-) had also increased significantly in E2-treated mice and were found 
in the kidneys. Splenocytes from E-2 treated mice produced significantly more 
Id540+ (a subset of IdLNF1+) IgG&M in vitro than splenocytes from control mice 
when incubated with control T cells, which is evidence for the pathogenic role of 
the Id LNF1-reactive T cells. Lastly, at 25 weeks of age, 80% of the estrogen-
treated mice had glomerular deposits of IdLNF1+ immunoglobulins (2). These 
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results point to the interaction of estrogen with immune cells. However, the ways 
in which estrogen modulates immune responses are still not yet well understood. 
Key to this knowledge would be an understanding of how estrogen interacts with 
its receptors. Two forms of estrogen receptors (ER), ERα and ERβ, have been 
identified. Each of these receptor subtypes or isoforms have been found to be 
normally expressed in immune cells (16-21).  
Thus, the purpose of this research project was to further investigate the 
influence of estrogen on autoimmunity, specifically in SLE. It has been suggested 
that estrogen may act on helper T lymphocytes (TH), which are an essential part of 
the normal immune response to antigens. Two types of TH cells are known: TH1 
and TH2 cells, which are distinguished by the specific cytokines they produce. 
TH1-type cytokines lead to pro-inflammatory responses in the host and while they 
participate in the initiation of autoimmune responses, they are protective later in 
disease.  TH2-type cytokines are important in immunoglobulin production and 
predominate in later disease (22). Experiments on male estrogen receptor (ER) 
knockout mice that were administered estrogen (E-2) showed that the shifts from 
TH2 to TH1 responses were protective while a TH2 response exacerbated 
autoimmune disease (16-21). These results suggested that estrogen has a 
differential effect in promoting TH1 and TH2 responses, as well as raise the 
question of the importance of the ER in inducing these responses since CD4+ T 
cells have been show to express ER. Consequently, the hypothesis that was tested 
in this project was that exposure to estrogen will lead to modulation of immune 
cells via interaction with the specific ERs that they express. To do this, we 
6 
 
exposed male ERα, ERβ and ERαβ knockout chimeric mice to chronic doses of 
estrogen with the aims of identifying the consequences of estrogen (E-2) exposure 
in the numbers and functions of immune cells, in order to determine whether these 
modulations resulted from the interaction of E-2 and ER expression. 
 
 
MATERIALS AND METHODS 
 
Derivation of ER deficient chimeric mice 
Thirty C57 Black 6 (C57BL/6) male mice were placed on an acid water 
regimen two days before irradiation to reduce nasal Pseudomonas infection. They 
were then irradiated with a total of 1100 rads, distributed in two doses, with five 
hours between the two irradiations. The day after irradiation, the mice were 
reconstituted with cells from donor bone marrow prepared from either of four 
types of male ER-deficient mice: wild type (WT), alpha knockout (αERKO), beta 
knockout (βERKO) or double knockout (αβERKO or KO/KO) for the E-2 
receptor.  To prepare the donor cells, 2-3 mice of the appropriate ER genotype 
were euthanized by CO2 asphyxiation.  Their femurs and tibias were removed and 
placed in a dish of sterile HBSS containing 5ml RPMI with 5% FBS. All muscle 
was removed from the bones. The ends were cut off and the bone marrow was 
flushed out using 5ml solution of RPMI with a syringe and a 25g needle. The 
marrow was flushed into another dish containing HBSS and was passed through a 
22g needle in order to break up the clumps. The mixture was then spun down and 
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suspended in media.  The cells were counted, and resuspended at a concentration 
of 1x107 cells/mL. 
Groups of seven irradiated recipient mice were reconstituted with 0.2 ml 
(5x106) of the appropriate cell type by intravenous injection in the tail vein. Two 
mice served as controls for irradiation and were not reconstituted. All mice were 
maintained on acid water, with antibiotics for one month. Within ten days of 
irradiation, the two control mice were moribund. This confirmed that the lethal 
irradiation was successful.  
Seven weeks after reconstitution, four mice from each group were injected 
with E-2 (17 β-estradiol valerate-1 mg/kg) in oil and three mice were injected 
with oil vehicle by bolus injection subcutaneously between the shoulder blades. 
These injections were performed subsequently every month (4 weeks) for 5 
months. Body weights were measured before each injection. This dosing regimen 
elevated mouse serum E-2 level to the peak physiological serum E-2 level in 
female mice of 150~200pg/ml (23). The level of E-2 was maintained for about 7 
days and decreased to normal levels found in male mice 2 weeks after treatment.  
 
Cell harvesting 
Two weeks after the 5th injection of estrogen, the treated and control mice 
were euthanized for experimental analysis. Body weight was recorded, and blood 
was collected. Tissue from thymus, spleen and kidneys were harvested 
individually from each mouse and cell suspensions were prepared in order to 
determine specific phenotypes. Red blood cells were lysed by resuspending the 
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cell suspension in 5mL TAC (tris-ammonium chloride), and the cells were 
counted.  
 
In vitro cytokine enzyme linked immunosorbent assay (ELISA) 
Lymphocytes from individual ER chimeric mice from each treatment 
group were cultured with Con A or idiopeptide aa62-73 (24-27). Cells and 
supernatant were collected on day 3 for cytokine production and day 7 for 
immunoglobulin production. Supernatants were frozen at -70º C until assays were 
conducted. ELISA was used to measure Interleukins 2, 4, 10, 12, IFNγ, to identify 
Th1/Th2-type cytokine shifts (R & D Diagnostics, e-Biosciences). Briefly, 96 
well Nunc Maxisorp plates were coated with 50µl of the appropriate dilution of 
anti-cytokine capture antibodies in 0.1M carbonate coating buffer pH 9.5 (IL-2, 
IL-4, IFN-γ) or 0.2M phosphate coating buffer pH 6.5 (IL-10 and IL-12). Plates 
were incubated overnight at 4 ºC, washed two times with PBS/0.05% Tween 
(wash solution), and then blocked with 50 µl  of the assay diluent (PBS/10%FBS 
pH7) for 1 hour at room temperature (RT). The plates were then washed two 
times, and cytokine standard and supernatant samples diluted 1:2 in assay diluents 
were added to the wells. After an overnight incubation at 4 ºC, the plates were 
washed three times with wash solution, and then 50µl of appropriately diluted 
biotin-conjugated detection antibodies was added to the wells and incubated 
overnight at 4 ºC. The plates were then washed four times, and 50µl strepavidin-
conjugated horseradish peroxidase (HRP), diluted 1:250 in assay diluent, was 
added and incubated for 30 minutes at RT. Lastly, the plates were washed five 
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times, and 50µl TMB substrate was added to each well. Color change 
corresponding to bound antibody was monitored for 15-30 minutes at RT, and 
then the reaction stopped by adding 50µl of H3PO4 to each well. The absorbance 
was then read at 450nm.  The concentration of each cytokine in the culture 
supernatant was determined from a standard curve.   
 
Table 1. Cytokine assays capture and detection antibody dilutions and standard 
range. 
Cytokines Capture Antibody 
Dilution 
Detection 
Antibody Dilution 
Standard 
Range (pg/mL) 
IL-2 1:250 1:250 0-200 
IL-4 1:250 1:250 0-500 
IL-10 1:1000 1:500 0-2000 
IL-12 1:250 1:250 0-100 
IFN-γ 1:1000 1:500 0-1000 
 
 
In vitro immunoglobulin ELISA 
For this assay, 96 well Immulon 1B plates were coated with 50µL per well 
of single-stranded DNA (ssDNA or double-stranded DNA (dsDNA) at 5µg/mL in 
1X SSC. The plates were incubated overnight at 4º C and were subsequently 
washed 2 times with PBS/1%Tween and 2 times with PBS. The plates were 
blocked with 50µL of PBS/1%Tween per well, incubated for an hour at RT and 
washed as previously described.  Then 50µL of each supernatant sample diluted 
1:2 in PBS/0.1%Tween in duplicate, was added to the wells of the plate and 
incubated overnight at 4º C.  The plates were washed twice with PBS/1%Tween 
and twice with PBS. Next 50µL of anti-goat IgM and IgG alkaline-phosphatase 
conjugate in PBS/0.1% Tween (1/2000 dilution) was added to all of the wells. 
The plates were incubated overnight at 4º C and washed as in previous steps. 
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Lastly, 50µL of substrate solution paranitrophenyl phosphate (PNPP) was added, 
and allowed to develop until color change was apparent (approximately 30 
minutes). Color development was then read at 405nm. 
 
Statistical analyses 
Data was analyzed by one-way ANOVA with post hoc comparisons by the 
Student-Newman-Keuls multiple comparisons test.  Differences in significance 
will be considered at p <0.05.   
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RESULTS 
 
Effect of estrogen treatment on survival of WT and estrogen receptor-deficient 
chimeric mice 
 
All WT mice survived throughout the duration of the experiment. 
Estrogen treated mice αERKO mice showed a lower survival rate than those that 
were treated with oil. One out of four mice died during the third month of 
injections. Mice from the βERKO estrogen treatment group also showed a lower 
survival rate than those that were treated with oil. There was one death out of four 
during the third month of injections. Additionally, estrogen-treated αβERKO mice 
also had a lower survival rate, with half of the mice in this group moribund within 
three months and four months of the experiment. This is in contrast with the 
control αβERKO mice which all survived the duration of the experiment.  
 
 
Table 2. Deaths of estrogen receptor-deficient chimeric mice. There were no 
deaths among any of the oil treated ER chimeric mice, while 1-2 mice from each 
E-2 treated ER KO chimera became moribund during the course of the injections. 
 
Treatment Groups Ratio of Death of Total Group 
Number 
WT + Oil 0 
WT + E-2 ¼ 
αERKO + Oil 0 
αERKO + E-2 ¼ 
βERKO + Oil 0 
βERKO + E-2 ¼ 
αβERKO + Oil 0 
αβERKO + E-2 ½ 
 
 Effect of estrogen treatment on body weights of WT and estrogen receptor
deficient chimeric mice
 
In general, oil treated (control) WT mice had higher body 
αβERKO, αERKO and 
lowered body weights in the WT and the ER
controls (Figure 1).
 
E2 treatment effect on body weight
 
βERKO control mice.   But estrogen treatment resulted in 
-deficient chimeras, compared to 
   
 
12 
-
weights than the 
 Figure 1. Body weights of 
weights were recorded before each estrogen injection at each time point for 
estrogen treated (n=4) and control (n=3) ER
 
 
a. WT mice 
The weights of the wild
significantly lower than the weights of the oil vehicle treatment group (p
value=0.014). Data showed that both groups averaged approximately the same 
weight at the first injections (25g), bu
injection, the WT oil
the estrogen-treated group weighed an average of 29.6g (+/
2.7g.  
 
 
estrogen receptor-deficient chimeric mice.
-chimeric mice. 
-type (WT) mice treated with estrogen were 
t diverged from then on.   At the final 
-treated mice had an average weight of 32.3g (+/
-2.1g), a difference of 
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 Body 
-
- 1.9g) while 
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b. αβERKO mice 
Data of body weights for the αβERKO mice showed that although the oil-
treated mice maintained slightly higher weights than estrogen-treated mice 
throughout the experiment, with the exception of the 5th injection, the weight 
differences were not significant. At the 5th injection, the average body weight of 
the αβERKO oil-treated mice was 5.7g higher than the estrogen-treated αβERKO 
mice, but this was not significant.  
 
c. αERKO mice 
The weights of the oil-treated αERKO chimeric mice were significantly 
higher that weights of estrogen-treated mice at later injections. On average, the 
oil-treated mice weighed 2.9g (+/- 2.4) more than the estrogen-treated groups, 
with the greatest significant difference of 5.6g (+/- 2.4) at the 5th time point (p-
value=0.01).   
 
d. βERKO mice 
The body weights of βERKO mice in both the oil and estrogen treatment 
groups were similar weight until the 4th injection, when the estrogen-treated mice 
showed a sharp decrease in body weight with a difference of 4.5g (+/- 2.5) 
between two groups at the 5th injection. This difference in weight, although not 
significant, persisted until the end of the study.  
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Effects of E2 receptor expression in the modulation of Th1 Cytokine production 
 
 Cells from each estrogen receptor chimeric mice were harvested and 
cultured with Con A or idiopeptide aa62-73, to determine the effects of ER 
receptor expression on cytokine production. An enzyme-linked immunosorbent 
assay (ELISA) was used to determine the relative amount of Th1 cytokines, IL-2, 
IFN-λ, IL-12, produced in media alone, Con-A and aa62-73. 
 
 
a. IL-2 
 
Cytokine production in cells cultured in media alone  
When cells were cultured in media alone, we found that there was no 
significant difference in IL-2 production by cells from the oil and estrogen-treated 
mice (Figure 2a). Interestingly, for the αERKO chimeric mice, the production of 
IL-2 by cells from estrogen-treated mice was significantly higher than production 
by cells from oil-treated mice (p=0.0038). There was no statistically significant 
difference in IL-2 production by cells from either βERKO or αβERKO chimeric 
mice, with or without estrogen treatment.  
 
 Figure 2a. Production of interleukin 2 (IL
chimeric mice treated with estrogen and vehicle.
treatment group were cultured in media alone (blank), media containing Con
mitogen. IL-2 cytokine production was meas
terms of optical density (OD) at 450nm.
*Indicates results of statistical significance (e.g. p
 
 
Con A–induced cytokine production
 Data showed a significantly higher production of Con
the WT control group, compared to the estrogen
2a). Thus, it appeared that E
Comparison of the different knockout groups showed that estrogen treatment d
not result in significant differences in IL
mice. Further, IL-
significantly higher than that produced by cells from WT mice.
 
 
 
 
-2) cytokines by cells from ER 
 Cells isolated from each 
ured by ELISA and expressed in 
 
-value<0.05) were found.
 
-A induced IL
-treated group (p =0.008)
-2 suppressed the production of IL-2 by the WT cells. 
-2 production compared to oil control 
2 production by cells from all of the knockout groups was 
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-2 in 
 (Figure 
id 
 
 Peptide 62-73 induced 
 In general, IL
and oil control chimeric receptor mice regardless of ER expression when cells 
were stimulated with peptide 62
production of IL-2 in the WT control group, compared to the estrogen group 
(p=0.04). Thus, similar to what we saw with Con
suppressed the production of aa62
Although IL-2 production was slightly
ERKO chimeric mice, the differences between the knockout groups were not 
statistically significant.
 
Figure 2b. Production of interleukin 2 (IL
chimeric mice treated with estrogen 
treatment group were cultured in media alone (blank) and aa62
(100µg/mL). IL-2 cytokine production was measured by ELISA and expressed in 
terms of optical density (OD) at 450nm.
* Indicates results of 
 
 
cytokine production 
-2 production was significantly higher in all estrogen
-73. Figure 2b shows a significantly higher 
-A, it appears that E
-73-induced IL-2 production in the WT cells. 
 higher for αβERKO cells that for the other 
 
-2) cytokines by cells from ER 
and vehicle. Cells isolated from each 
-73 peptide 
 
statistical significance (e.g. p-value<0.05) were found.
17 
-treated 
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 b. IFN-gamma 
 
Cytokine production in cells cultured in media alone 
Unstimulated c
higher levels of IFN
0.018) (Figure 3a)
mice; however this increase was not significant. In contrast, IFN
cells from βERKO mice treated with oil was greater than that produced by cells 
from mice that had been treated with E
 
Figure 3a. Production of interferon
chimeric mice treated with estrogen and vehicle.
treatment group were cultured in media alone (blank) and media containing Con
A mitogen. IFN-γ cytokine
terms of optical density (OD) at 450nm. 
* Indicates results of statistical significance (e.g. p
 
 
 
ells from WT mice treated with E-2 produced relatively 
-γ compared to cells from WT mice treated with oil (p
.  Similar results were also seen for αERKO and 
-
-2.  
-γ (IFN-γ) cytokines by cells from ER 
 Cells isolated from each 
 production was measured by ELISA and expressed in 
 
-value<0.05) were found.
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-value= 
αβERKO 
γ production by 
 
-
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Con A-induced cytokine production  
Overall, Con-A stimulated cells showed higher productions of IFN-γ 
compared to cells that were cultured in media alone or with peptide 62-73 (Figure 
3a). Production by cells from WT mice treated with oil was slightly higher than 
that produced by WT mice treated with E-2; however this increase was not 
statistically significant. There was no difference in IFN-gamma production by 
cells from the oil or estrogen treated αERKO mice.  Data showed a higher 
production of the cytokine by cells from the βERKO E-2 treated group as opposed 
to cells from the βERKO control group (p-value=0.018). IFN-gamma levels 
produced by cells from either the oil or the E-2 treated βERKO group were also 
higher than those observed for any of the other WT or receptor knockout groups. 
Finally, while the amount of IFN-γ produced by cells from the αβERKO control 
group was higher than that produced by cells in the E-2 treated group, this 
difference was not statistically significant. 
 
Peptide 62-73 induced cytokine production  
Production of IFN-γ by cells from WT mice treated with E-2 stimulated 
with peptide 62-73 was greater than that produced by cells from WT mice treated 
with oil (p-value=0.018) (Figure 3b).  In general, however, IFN-gamma 
production by cells from WT mice treated with oil was higher than levels 
produced by cells from αERKO and βERKO chimeric mice, but similar to that 
produced by cells from αβERKO mice.  Further, cells from αβERKO chimeric 
mice treated with E-2 produced slightly higher levels of IFN-γ compared to cells 
 from αβERKO chimeric oil
αERKO and βERKO mice.
 
 
Figure 3b. Production of interferon
chimeric mice treated with estrogen and vehicle.
treatment group were cultured in media alone (alone) and media containing 
aa62-73 peptide (100
and expressed in terms of optical density (OD) at 450nm. 
* Indicates results of
 
 
 
 
c. IL-12 
 
Cytokine production in cells cultured in media alone 
Unstimulated cells from WT mice treated with E
production of IL-12 than cells from WT mice treated with oil, alth
difference was not statistically significant
showed no significant differences in IL
differences were seen for cells from the 
-treated control mice, while no effect was seen in the 
 
-γ (IFN-γ) cytokines by cells from ER 
 Cells isolated from each 
µg/mL). IFN-γ cytokine production was measured by ELISA 
 
 statistical significance (e.g. p-value<0.05) were found.
 
-2 displayed greater 
 (Figure 4a).  Cells from α
-12 production; however, significant 
βERKO treatment groups. Cells from E
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ough this 
ERKO mice 
-2 
 treated βERKO chimeric mice produced more IL
treated βERKO control mice (p
 
 
Figure 4a. Production of interleukin 12 (IL
chimeric mice treated with estrogen and vehicle.
treatment group were cultured in media alone (blank) and media containing Con
A mitogen. IL-12 cytokine production was measured by ELISA and expressed in 
terms of optical density (OD) at 450nm.
* Indicates results of statistical s
 
 
Con A-induced cytokine production
IL-12 production 
treated with E-2 compared to that produced by cells from WT mice treated with 
oil. On the other hand, 
levels of IL-12 than cells from the 
not statistically significant. Cells from 
-12 than cells from the oil
-value=0.01). 
-12) cytokine by cells from ER 
 Cells isolated from each 
 
ignificance (e.g. p-value<0.05) were found.
 
in response to Con was increased in cells from WT mice 
cells from αERKO mice treated with E-2 produced lower 
αERKO oil control mice, but these results were 
αβERKO mice treated with estrogen 
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 produced significantly less IL
differences were observed for 
 
 
Figure 4b. Production of interleukin 12 (IL
chimeric mice treated with estrogen and vehicle.
treatment group were c
aa62-73 peptide (100
and expressed in terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. p
 
Peptide 62-73 induced cytokine production 
 IL-12 production in WT cells 
higher than for the other receptor chimera groups, with cells from 
treated group producing the lowest levels
treated with E-2 and stimulated with peptide 62 produced significantly higher 
levels of IL-12 compared to cells from mice treated with oil (p
significant differences in IL
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differences for αβERKO mice. Cells from E-2 treated αβERKO chimeric mice 
produced lower levels of IL-12 compared to cells from αβERKO mice treated 
with oil (p-value=0.007). 
 
Effects of E2 receptor expression on the modulation of Th2 cytokine production 
Cytokine ELISA was used to determine the relative amount of Th2 cytokines, 
IL-4 and IL-10, produced by cells from estrogen or oil treated WT or ER chimeric 
mice cultured in media alone, or with Con-A or aa62-73. 
 
a. IL-4 
 
 
Cytokine production in cells cultured in media alone 
There was no significant difference in IL-4 production by unstimulated 
cells from the WT oil and estrogen-treated mice, although IL-4 levels in the E-2 
treated mice were slightly higher (Figure 5a). There was also no significant 
difference in IL-4 production by cells from αERKO and αβERKO chimeric mice.  
However, cells from βERKO chimeric mice treated with estrogen produced 
significantly less IL-4 than cells from oil-treated mice (p-value= 0.006). 
 
 Figure 5a. Production of interleukin 4 (IL
chimeric mice treated with estrogen and vehicle.
treatment group were cultured 
A mitogen. IL-4 cytokine production was measured by ELISA and expressed in 
terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. p
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Figure 5b. Production of interleukin 4 (IL
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 b. IL-10 
 
Cytokine production in cells cultured in media alone
IL-10 production by cells from WT mice treated with E
media alone, was greater than that by cells from WT oil
this difference was not statistically significantly different
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of IL-10 than their oil control counterparts (p
the αβERKO mice (p
lower levels of IL
 
Figure 6a. Production of interleukin 10 (IL
chimeric mice treated with estrogen and vehicle.
treatment group were cultured in media alone (blank) and media containing Con
A mitogen. IL-10 cytokine production was measured by ELISA and expressed in 
terms of optical density (OD) at 450nm. 
* Indicates results of statistical significance (e.g. p
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Con A-induced cytokine production  
Cells from WT mice treated with E-2 and cultured in Con-A produced 
higher levels of IL-10 compared to WT control mice; however this difference was 
not statistically significantly different (Figure 6a).  In general, cytokine levels 
produced by cells from the oil or E-2 treated WT were higher than levels 
produced by cells from the other ER chimeric mice. This difference was 
particularly significant when compared to IL-10 levels produced by cells from 
βERKO chimeric mice (p-value=3.78x10-11). Cells from αERKO mice treated 
with E-2 produced significantly lower levels of IL-10 compared to cells from 
control αERKO (p-value=0.001). The same trend was seen in cells from βERKO 
mice (p-value=7.0x10-4) and αβERKO mice (p-value=0.005). In general, cells 
from βERKO mice in both estrogen and oil treatment groups produced lower 
levels of IL-10 than cells from the WT, αERKO and αβERKO groups. Cells from 
αβERKO mice treated estrogen or oil also produced greater amounts of cytokine 
than αERKO and more significantly βERKO cells (p-value=4.42x10-9).  
 
 Figure 6b. Production of interleukin 10 (IL
chimeric mice treated with estro
treatment group were cultured in media alone (blank) and media containing 
aa62-73 peptide (100
and expressed in terms of optical density (OD) at 450nm. 
* Indicates results of statistical significance (e.g. p
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hand, cells from αβERKO mice treated with E-2 produced slightly higher levels 
of IL-10 compared to αβERKO controls treated with oil. 
 
Effects of ER expression on anti-single stranded DNA total immunoglobulin 
(IgG and IgM) production 
Cell culture supernatant from each group of estrogen receptor chimeric 
mice was tested in an ELISA to determine the relative amount of anti-single 
stranded DNA total IgG and IgM produced in the presence of media alone, LPS 
or aa62-73. 
 
a. Anti-ssDNA immunoglobulin production in cells cultured in media alone 
Figure 7 shows the levels of anti-single stranded DNA antibodies (IgG and 
IgM) produced by unstimulated cells in each ER knockout chimera group of mice. 
In general, antibody production was highest for cells from αERKO mice and 
lowest for cells from αβERKO mice. Differences in total immunoglobulin 
production in WT estrogen-treated and control mice were recorded, however, they 
were not of statistical significance. In contrast, there was a significant difference 
in the production of total immunoglobulin by cells from both αERKO and 
βERKO mice. Cells from αERKO mice treated with oil produced increased anti-
ssDNA antibodies compared to cells from αERKO mice treated with E-2 (p-
value=0.006). A similar trend was observed between control cells from βERKO 
mice and cells from βERKO mice treated with E-2 (p-value=0.02). We also noted 
a significant increase in antibody production by cells from αERKO mice treated 
 with E-2 compared to cells from WT 
Cells from βERKO mice treated with oil only also produced higher levels of 
immunoglobulin compared to WT cells treated with oil (p
 
Figure 7. Effects of ER expression on anti
production by unstimulated cells from ER chimeric mice treated with estrogen 
and vehicle. Cells isolated from each treatment group were cultured in media 
alone (blank), media containing lipo
Immunoglobulin production was measured by ELISA and expressed in terms of 
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. p
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Figure 8. Effects of ER expression on anti
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peptide. Immunoglobulin production was measured by ELISA and expressed in 
terms of optical density (OD) at 405nm.
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Figure 9. Effects of ER expression on anti-single stranded DNA IgG and IgM 
production by aa62-73-stimulated cells from ER chimeric mice treated with 
estrogen and vehicle. Cells isolated from each treatment group were cultured in 
media alone (blank), media containing lipopolysaccharides (LPS), and aa62-73 
peptide. Immunoglobulin production was measured by ELISA and expressed in 
terms of optical density (OD) at 405nm. 
* Indicates results of statistical significance (e.g. p-value<0.05) were found 
 
Effects of ER expression in the modulation of anti-double stranded DNA total 
immunoglobulin (IgG and IgM) production 
Cells from each estrogen receptor chimeric mouse were harvested and an 
ELISA was used to determine the relative amount of total anti-double stranded 
DNA IgG and IgM produced in media alone, LPS and aa62-73. 
 
a. Anti-dsDNA immunoglobulin production in cells cultured in media alone 
 
Figure 10 shows the levels of anti-double stranded DNA antibodies (IgG 
and IgM) produced by unstimulated cells for each ER knockout chimera group. 
Generally, the production of anti-dsDNA antibodies was similar for all treatment 
groups except for a statistically significant increase in the production of 
antibodies by cells from αERKO chimeric mice treated with oil as compared to 
cells from the WT mice (p-value=0.01). 
 Figure 10. Effects of ER expression
production by unstimulated cells from ER chimeric mice treated with estrogen 
and vehicle. Cells isolated from each treatment group were cultured in media 
alone, media containing lipopolysaccharides (LPS), and aa62
Immunoglobulin production was measured by ELISA and expressed in terms of 
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. p
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Figure 11 compares anti
production by cells stimulated with LPS in the different ER knockout chimera 
mice. The only significant difference found was an increase in anti
immunoglobulin production in estrogen treated cells
compared to cells from 
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 Figure 11. Effects of ER expression on anti
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Immunoglobulin production was measured by ELISA and expressed in terms of 
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Figure 12. Effects of ER expression on anti
by aa62-73-stimulated cells from ER chimeric mice treated with estrogen and 
vehicle. Cells isolated from each treatment group were cultured in media alone, 
media containing lipopolysaccharides (LPS), and aa62
Immunoglobulin production was measured by ELISA 
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. p
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DISCUSSION 
 
The higher occurrence of SLE in females versus males, as well as the 
significant increase in the disease incidence in females after puberty, and the 
fluctuation in disease severity throughout the menstrual cycle and pregnancy 
suggests that sex hormones, specifically the female sex hormone estrogen, play an 
important role in SLE and in autoimmunity (6, 7). This project sought to gain 
further knowledge about the mechanisms by which estrogen mediates immune 
responses that could explain the predilection of SLE in females.   Particularly, we 
investigated the significance of estrogen’s interactions with its various receptors 
in modulating TH1 and TH2 immune response, since TH2-type cytokines 
predominate in SLE.   To address this question we examined cytokine and 
autoantibody production in estrogen and oil vehicle-treated estrogen-receptor 
knockout chimeric mice.  In these mice, ER receptor expression was modulated 
on immune cells only, so that these cells expressed only ER-α, ER-β, or no ER, 
while non-immune cells expressed normal levels and types of all estrogen 
receptor isoforms.  The results in these mice were compared to results in WT 
mice, which would express both ER.  In addition, only male mice were used, in 
order to obviate the effects of physiological levels of estrogen. 
 
First, we looked at the effect of E-2 treatment on body weight. No body 
weight differences were seen between the mice prior to estrogen treatment period. 
E-2 administration of 1mg/kg monthly to male WT C57/black 6 mice and the 
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three ER receptor knockout chimeric groups led to a decrease in survival rate, as 
well as weight loss, compared to the control mice treated with oil vehicle only. 
There was a lower survival and a significant decrease in body in estrogen treated 
WT mice compare to the control oil-treated WT mice. The same trend was seen in 
αERKO chimeric mice. Estrogen-treated mice in the βERKO and αβERKO 
chimera groups also showed a large decrease in body weight, but only after the 4th 
injection of E-2. The difference was particularly significant for the WT and 
αERKO chimeric mice, suggesting a differential effect of α and β receptors in 
mediating estrogen-induced cytokine production, with ER-α possibly playing a 
greater role.  Our observations for estrogen and oil treated WT mice are in 
agreement with results reported by Feng et al. (28), which looked at the 
development of lupus nephritis in αERKO mice and reported a significant 
decrease in weight in WT mice treated with E-2.  Other studies in both human and 
animal models (29-32) have shown that estrogens serve to mobilize body fat and 
induce the apoptosis of adipose tissue, thereby leading to a decrease in body 
weight. This effect seems to be quite rapid; in fact, in the current study, body 
weights of E-2 treated WT mice decreased significantly following the first and 
second injections and remained lower than the control mice throughout the 
duration of the experiment.  
However, in contrast to our data, Feng et al. (28) did not observe a 
significant difference in body weights in E-2-treated αERKO mice compared to 
those treated with oil.  However, in the previous work, the mice studied were ER-
α knockout mice and not ER-α knockout chimeric mice; the former would not 
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express ER receptors on any cells or tissue while, the latter would be deficient in 
ER expression on immune cells only, but other cells and tissues in the recipient 
mice would express ER-α. This suggests that in our studies, estrogen’s effect in 
the modulation of body weight was mediated by expression of ER-α on non-
immune cells. 
Other research has shown varying effects of the sex hormone estrogen on 
autoimmune disease manifestation. Some studies have shown that estrogen has 
immunosuppressive effects in some organ-specific autoimmune diseases. One 
study revealed that administration of E-2 to αERKO C57BL/6 mice resulted in the 
suppression of the clinical signs of Experimental Autoimmune Encephalomyelitis 
(EAE), an animal model of the autoimmune disease Multiple Sclerosis (MS) (33). 
It has also been observed that the severity of multiple sclerosis in human 
decreases as sex hormone levels increase during pregnancy, but this effect is 
reversed postpartum due to alterations in sex hormones (34-36). Another study of 
MS reported an enhanced stimulation of IL-10 secretion at pregnancy levels of E-
2, as well as an increase in IFN-γ in patients with the disease (37). On the other 
hand, estrogen exposure has been shown to accelerate systemic autoimmune 
diseases.  Together, these findings have supported the important role of sex 
hormones on immune responses and specifically autoimmune diseases.  
One explanation for the differences in the response to estrogen in organ-
specific and systemic autoimmune diseases could be its role in cytokine 
production.  Estrogen stimulates the production of TH2 cytokines and promotes 
interactions between T and B cells. It has also been reported that estrogen leads to 
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increased secretion of IL-4, IL-5, IL-6 and IL-10 by TH2 lymphocytes (4, 38-40). 
These cytokines stimulate the proliferation antibody-producing B cells. SLE 
patients have increased levels of IL-6 and IL-10, which can be directly correlated 
with clinical disease severity (39, 40). Increased levels of IL-4 in NZB/W and 
MRL/lpr mice are also evident.  
In our project, both TH1 and TH2 cytokine production was determined 
using ELISA. Our findings show that when cells were cultured in media alone, in 
the absence of any antigen or mitogen, IL-4 and IL-10 production by cells from 
estrogen-treated WT mice was generally higher compared to cells from control 
WT mice. Although these results were not statistically significant, they point to a 
role for estrogen in TH2 cytokine production.  Consistent with the findings of 
Feng et al (28), which reported that serum levels of TH2 cytokines were not 
increased in oil and estrogen-treated αERKO mice, we did not find differences in 
cytokine production by cells from oil or estrogen-treated αERKO knockout 
chimeric mice.   This suggested that ERβ, which would be expressed in the ERα 
KO chimeric mice, is likely not involved in estrogen-induced TH2 cytokine 
production.  Interestingly, our results showed a decreased in both IL-4 and IL-10 
production by cells from estrogen-treated βERKO mice compared to oil-treated 
βERKO mice, suggesting that estrogen-induced modulation of TH2 cytokines 
production may be mediated by ER-α expression. Furthermore, this trend was 
similar across all cytokines examined, both TH1 and TH2, as consistently lower 
levels of cytokines were produced by βERKO cells treated with E-2 compared to 
those treated with oil vehicle.   Production of IL-4 by cells from both αERKO and 
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αβERKO mice did not prove to be statistically significant. However, IL-10 
production followed a similar trend for αβERKO as for βERKO cells, discussed 
previously, with decreased production of the cytokine in αβERKO estrogen-
treated mice versus oil-treated mice. Taken together, these results point to the 
importance of ER-α in estrogen-mediated TH2 cytokine production and a potential 
role for ER-β in down-regulating this response, particularly with respect to IL-10 
levels. 
In response to Concanavalin A (Con A) WT mice treated with estrogen 
produced higher levels of IL-4 and IL-10, although the increase in IL-10 levels 
was not significant.  We also observed a decrease in IL-4 and IL-10 production in 
βERKO mice treated with estrogen compared to βERKO mice treated with oil. 
This further supports the conclusion that estrogen-induced TH2 cytokine 
modulation is not mediated by the ER-β isoform. Interestingly, a similar trend 
was observed for IL-10 production by cells from αERKO mice.  This suggests 
that expression of both receptors is important in estrogen-induced TH2 cytokine 
production after mitogen stimulation, with one or the other playing a more 
predominant modulatory role depending on the specific cytokine. 
We also looked at specific cytokine production in response to the 
pathogenic idiopeptide, aa62-73. As expected from previous data (28), stimulation 
of cells with the pathogenic IdLNF1 antigen resulted in an increase in TH2 cytokine 
(IL-10) in cells from WT mice treated with estrogen compared to those treated 
with oil only, although this difference was not statistically significant. This result 
suggests that the pathogenic response in lupus nephritis may be enhanced directly 
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by estrogen treatment. Interestingly, production was significantly decreased in 
cells from αERKO mice treated with estrogen when compared to oil treated 
αERKO mice. We found a similar trend for βERKO mice. These results suggest 
that both ER receptors are important in estrogen-induced TH2 cytokine production 
in response to pathogenic autoimmune peptides. 
While in most autoimmune diseases, TH2 cytokines (IL-4, IL-10, and IL-
6) are important in later stages of disease, pro-inflammatory TH1 cytokines (IL-2, 
IFN-γ, IL-12) are essential in initiation of pathology.  Cytokine production in 
male estrogen receptor (ER) knockout mice that were administered estrogen (E-2) 
showed that the shifts from TH2 to TH1 responses were protective while a TH2 
response exacerbated autoimmune disease (28). To further define the role of ER 
in this process, we measured TH1 cytokine production in estrogen-treated ERKO 
chimeric mice.  Cells from αERKO chimeric mice treated with E-2 and cultured 
in media alone produced higher levels of IL-2 and IFN-y (but not IL-12) than 
those mice treated with oil. Interestingly, this result was different from that 
observed by Feng et al, who found no differences in TH1 cytokine production by 
cells from αERKO mice.   However, differences in ER expression between the 
two models, as discussed previously, may have contributed to this difference.  
Conversely, as expected, Il-12 and IFN-γ production in WT mice was greater in 
the estrogen treatment group compared to the oil treatment group.  These data are  
in agreement with previous studies that supported a role for IFN-γ in the onset, 
but not later stages, of autoimmune disease (27). 
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Mitogen-induced IL-2 and IFN-γ production by cells from WT estrogen-
treated mice was decreased compared to cells from WT oil-treated mice. From 
this observation, it appears that TH1 cytokine production was suppressed by the 
administration of estrogen in wild type mice, and this suppression may be 
mediated by ER. This was further supported by the observation that there were no 
differences in IL-2 production in any of the estrogen-treated ER knockout 
chimeric mice. Interestingly, however, we found that IFN-γ production by cells 
from estrogen-treated βERKO mice was greater compared to that produced by 
cells from control βERKO mice.  This, combined with the fact that no differences 
were found for αERKO mice, suggests a role of ER-α in IFN-γ production.  In the 
case of IL-12 production, we noted that levels produced by cells from αERKO 
and αβERKO estrogen-treated mice were decreased compared to the oil controls 
of these groups, while the opposite results were seen for βERKO mice.   Thus it 
appears that ER-α expression may play a role in IFN-γ and IL-2 production but 
not in IL-12 production. Additionally, because none of the cells from ER 
knockout chimeric mice treated with estrogen showed any significant changes in 
IL-2 production compared to the oil treatment groups, it is possible that both ER-
α and ER-β expression on immune cells play significant roles in promoting the 
estrogen-induced TH1 cytokine production.  
Finally, we found that in general, there was greater production of TH1 
cytokines in the presence of the idiopeptide 62-73. While there was an increase in 
IL-2 levels produced by cells from WT control mice compared to cells from 
estrogen-treated mice, the opposite was observed for both IL-12 and IFN-γ, with 
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cells from estrogen-treated mice producing higher levels of these cytokines.  Our 
results for IFN-γ were consistent with previous research (41), which reported an 
increase in IFN-γ –producing cells in castrated female C57BL/6 mice, which was 
ER-α and not ER-β dependent.  However, with the exception of IL-12, we did not 
find differences in TH1 cytokine production in αERKO, βERKO or αβERKO 
mice.  Thus our data suggests the importance of both ER-α and ER-β in estrogen-
induced modulation of the pathogenic autoantibody response, with ER-α 
expression being possibly more significant.   Differences in the levels of 
expression of each ER isoform, as observed by Feng et al (28) may also play a 
role; in that study,  ER-α was found to be expressed in a higher density than ER-β 
on immune cells,  which could explain why it may play a more significant role 
than ER-β in modulating the immune response.  Further, levels of ER were higher 
in mice that were genetically susceptible to develop autoimmune disease relative 
to MHC haploype-matched nonautoimmune mice.  Finally, another study showed 
that estrogen exposure directly activated T cells through the cell membrane ER-α 
(42). Thus, differences in the numbers of each ER isoform expressed on the 
immune cells of certain individuals could explain differences in T cell responses 
to antigen, which could contribute to the development of autoimmune diseases.  If 
the levels of receptor expression between males and females also differ, this could 
play a role in the predominance of autoimmune diseases in females as opposed to 
their male counterparts. 
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To further explore the role of ER expression in modulating the immune 
response, particularly in terms of the development of autoimmunity, the effect of 
ER-α and ER-β expression on estrogen-induced modulation of anti-single 
stranded DNA and anti-double stranded DNA immunoglobulin levels was also 
determined. Interestingly, we found that B cells from both αERKO and βERKO 
mice treated with estrogen produced less anti-single stranded DNA than oil-
treated mice. This same trend was seen in WT mice, although the difference was 
not significant. Compared to cells from oil-treated WT mice, cells from oil-treated 
βERKO mice produced significantly less immunoglobulin. Conversely, compared 
to WT estrogen treated mice, cells from αERKO chimeras treated with estrogen 
produced significantly greater levels of immunoglobulin. These data would 
suggest a potential role for E-2 in modulating immunoglobulin production that 
may involve estrogen interaction with both ER isoforms. The latter conclusion is 
further supported by the observations that αERKO chimeric mice treated with E-2 
produced greater amounts of anti-single stranded DNA immunoglobulin when 
compared to cells from WT mice treated with E-2, as well as the fact that cells 
from βERKO mice treated with oil produced higher levels of immunoglobulin 
compared to WT cells treated with oil. These results suggest that ER-β expression 
might have an up-regulating effect on E-2 mediated anti-single stranded DNA 
immunoglobulin production, while the presence of ER-α expression would have a 
down-regulating effect.  
LPS-induced anti-single stranded DNA antibody production was increased 
in both control and E-2 treated mice in all of the ERKO chimeric mice when 
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compared to WT mice. This supports the idea that both ER-α and ER-β are 
involved in anti-single stranded DNA immunoglobulin modulation by estrogen. In 
the presence of IdLNF1 antigen (peptide 62-73), we found lower anti-single 
stranded antibody production by cells from WT mice treated with estrogen when 
compared to cells from WT mice treated with oil, suggesting that E-2 may 
suppress the pathogenic B cell response to the antigen.  We found that in the 
presence of IdLNF1 antigen, as in the absence of it, there was a significant increase 
in antibody production in cells from αERKO mice treated with estrogen compared 
to E-2 cells from WT mice. However, no significant differences were found when 
βERKO chimeric mice were compared to WT, suggesting that ER-β expression 
was important in this response. 
Previous studies have reported that the production of anti-double-stranded 
DNA antibody is a specific biomarker for SLE in some patients (26).  When cells 
were cultured in media alone, we found a significant increase in production of 
anti-DNA specific immunoglobulin by cells from αERKO mice treated with oil 
when compared to cells from WT mice treated with oil, suggestive of the role of 
ER-β expression in production of this antibody.  No differences were found with 
regard to E-2 treatment.  However, LPS-induced anti-DNA specific 
immunoglobulin production was increased when cells from βERKO E-2 mice 
were compared to βERKO control mice , suggesting that in mitogen-induced 
immunoglobulin production, ER-α may be involved.-  
In the presence of IdLNF1 antigen, as expected from previous studies (28), 
we found an increase in immunoglobulin production by cells from Wild Type 
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mice after E-2 administration compared to control. This result points to a role of 
E-2 in modulating pathogenic autoantibody production. We also found that anti-
double stranded DNA antibody production by cells from αERKO estrogen treated 
mice was decreased compared to αERKO oil-treated cells. The same trend was 
seen in βERKO mice, suggesting that both ER-α and ER-β may be important in 
this response. Significantly greater levels of total immunoglobulin was produced 
by cells from estrogen treated αERKO and βERKO mice compared to WT mice 
treated with estrogen. These data taken together suggest that ER-α and ER-β may 
modulate pathogenic autoantibody-producing B cell responses. Our data also 
showed that compared to the cells form oil-treated WT mice, cells from oil-
treated αβERKO produced less  ani-DNA antibody while the opposite was seen 
when estrogen treated cells from these two groups were compared.  This further 
supports a role for estrogen in exacerbating the pathogenic B cell response. 
In conclusion, our results provide further evidence supporting a critical 
role for E-2 in triggering and/or modulating the development of autoimmune 
lupus nephritis through its effect on cytokine production, since in general we saw 
an increase in the levels of TH2 cytokines with estrogen treatment, as well as an 
increase in levels of the TH1 cytokine IFN-γ.  Results from our study also 
provided evidence supporting a significant role for both ER-α and ER-β in the 
development of theautoimmune disease cytokine and Ig profile, with ER-α have a 
more significant effect. These findings support a role for estrogen and ER, and 
may, in part, explain the increased incidence of autoimmune diseases in females.   
Given our findings, the use of estrogen in contraceptives, hormone replacement 
therapy and dietary supplements should continue to be evaluated. 
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WRITTEN CAPSTONE SUMMARY 
 
Project Description 
Approximately 5 percent of the population in Western countries is affected 
by various autoimmune diseases (1). The immune system is essential in the 
recognition of and distinction between self and non-self entities.  A typical 
immune system only generates a humoral (antibody-specific) and/or cellular 
response to non-self such as pathogens, bacteria, antigens etc. However, in some 
cases the immune system may recognize an individual’s own cells and proteins as 
foreign, causing an autoimmune response. Contrary to what might have been 
thought initially, autoimmunity is a normal process that is important in clearing 
the body of certain pathological self cells (such as the prevention of tumor 
metastasis) and cellular debris.  
According to Davidson and Diamond (2001), autoimmune disease is 
defined as a clinical syndrome caused by the activation of T or B cells, or both, in 
the absence of an ongoing infection or other discernible cause. In other words, 
autoimmune disease is caused by the failure of the proper functioning of the 
body’s defense mechanisms, or a lack of tolerance of one’s own cells. There exist 
two categories of autoimmune diseases. Organ-specific autoimmune diseases, 
such as type 1 diabetes mellitus, are localized in specific tissues in the body. 
Systemic diseases, such as systemic lupus erythematosus (SLE), have a 
widespread effect on several tissue systems in the organism. In general, these 
diseases are caused by, either changes in selection and regulation of T cells or B 
cells, or aberrant reactions to particular self or foreign antibodies (1). 
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Various studies have noted a significant sex difference in immune 
responses to antigens. It appears that females in many species are seen to have 
heightened immune responses and are more susceptible to autoimmunity (2, 3). 
Particularly, in Systemic Lupus Erythematosus (SLE), we see a 9:1 ratio in 
predominance of the disease in women as compared to men (6, 7). There is also 
evidence of the correlation between steroid hormone levels and the changes in 
clinical manifestation of SLE, which is additionally enhanced during pregnancy 
and the postpartum period (8-10).  Male and female patients with SLE often have 
abnormally high levels of estrogen (hyperestrogenic) and/or abnormally low 
levels of androgen (testosterone) hypoandrogenic (11-13). This correlation is also 
reinforced by the higher incidence of the disease in patients with Klinefelter’s 
syndrome (14, 15), which is a genetic disease of males that is characterized by a 
variety of sex hormone abnormalities, including increased production of estrogen.  
These data, therefore, point to a potential significant role of estrogen in the 
gender-specific modulation of immune responses involved in autoimmunity. 
However, the ways in which estrogen modulates immune responses are still not 
yet well understood. Key to this knowledge would be an understanding of how 
estrogen interacts with its receptors. Two forms of estrogen receptors (ER) have 
been identified, ERα and ERβ. Each of these receptor subtypes or isoforms have 
been found to be normally expressed in immune cells (16-21). The purpose of this 
research project was to further investigate the influence of estrogen on 
autoimmunity, specifically in SLE. It has been suggested that estrogen may act on 
helper T lymphocytes (TH), which are an essential part of the normal immune 
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response to antigens. Two types of TH cells are known: TH1 and TH2 cells, which 
are distinguished by the specific cytokines they produce. TH1-type cytokines lead 
to pro-inflammatory responses and while they participate in the initiation of 
autoimmune responses, they are protective later in disease.  TH2-type cytokines 
are important in immunoglobulin production and predominate in later disease 
(22).  
Experiments on male estrogen receptor knockout mice that were 
administered estrogen showed that the shifts from TH2 to TH1 responses were 
protective while a TH2 response exacerbated autoimmune disease (16-21). These 
results suggested that estrogen has a differential effect in promoting TH1 and TH2 
responses, as well as raise the question of the importance of the ER in inducing 
these responses. Consequently, the hypothesis that was tested in this project was 
that exposure to estrogen will lead to modulation of immune cells though an 
interaction with the specific ERs that they express. This hypothesis was tested by 
exposing male ERα, ERβ and ERαβ knockout chimeric mice to chronic doses of 
estrogen with the aims of identifying the consequences of estrogen exposure in 
the numbers and functions of immune cells, to determine whether these 
modulations resulted from the interaction of estrogen and its receptors. 
 
Methods 
Thirty C57 Black 6 (C57BL/6) male mice were irradiated with a total of 
1100 rads. The day after irradiation, the mice were reconstituted with cells from 
donor bone marrow prepared from either of four types of male estrogen receptor 
(ER)-deficient mice: wild type (WT), alpha knockout (αERKO), beta knockout 
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(βERKO) or double knockout (αβERKO or KO/KO) for the ER.  Donor cells 
were prepared from 2-3 mice of the appropriate ER genotype, which were 
euthanized by CO2 asphyxiation.  Their femurs and tibias were removed and all 
muscle was removed from the bones. The ends were cut off and the bone marrow 
was flushed out. The marrow was flushed into another dish containing and the 
clumps were broken. The mixture was then spun down and suspended in media. 
Groups of seven irradiated recipient mice were reconstituted the appropriate 
donor cell type. Two mice served as controls for irradiation and were not 
reconstituted and within ten days of irradiation, these mice were moribund. This 
confirmed that the lethal irradiation was successful.  
Seven weeks after reconstitution, four mice from each group were injected 
estrogen in oil and three mice were injected with oil vehicle by subcutaneous 
injection between the shoulder blades. These injections were performed 
subsequently every month (4 weeks) for 5 months. Body weights were measured 
before each injection. In order to study the effect of this estrogen treatment on 
immunity and specifically the production of cytokines and immunoglobulin, the 
mice were euthanized and their cells were harvested. We performed an enzyme-
linked immunosorbent assay (ELISA) on these cells suspensions.  
Project Significance 
As aforementioned, much has yet to be understood about the mechanisms 
through with the sex hormone modulates autoimmune disease. Various autoimmune 
diseases, including lupus and rheumatoid arthritis have been shown to modulate in their 
clinical manifestation according to levels of estrogen. In fact, in addition to the gender 
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bias, lupus is also seen to manifest itself predominantly in women in child-bearing age. In 
light of this, the current project provides further evidence that estrogen plays a 
critical role in triggering the development of autoimmune lupus nephritis through 
its effect on cytokine production, since in general we saw an increase in TH2 
cytokines, leading to activation of B cells and the production of auto-antibodies, 
with estrogen treatment. We also observed an increase in TH1 cytokine IFN-γ 
which is thought to play an important role in initiating autoimmune disease. 
Results from estrogen receptor knockout mice also provided evidence that both 
estrogen receptor subtypes, ER-α and ER-β, play significant roles in the 
autoimmunity disease cytokine and immunoglobulin profile. Our results also 
suggested that ER-α might have a more significant effect.  
These findings support a role for estrogen and ER in the increased 
incidence of autoimmune diseases in females.  This study is significant in light of 
the growing use of estrogen in contraceptive, hormone replacement therapy and 
various dietary supplements nowadays. It is important for individuals who have 
been diagnosed with autoimmune disease to learn more about their condition and 
the mechanisms involved in order to better manage and cope with it. Furthermore, 
the findings from this project and others have been conducted in the field serve to 
open new avenues for the devising therapeutic agent that will specifically target 
the different mechanisms involved in autoimmune disease manifestation and 
progression. 
 
